Physician profile
Terri Martin
NPI 1093830150
$934.78
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $729 · 2020: $192 · 2021: $12.98.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $199.97 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $134.52 | 2019-2020 | |
| Lilly USA, LLC | $116.59 | 2019 | |
| Pfizer INC. | $92.67 | 2019 | |
| Janssen Biotech, INC. | $63.72 | 2019-2020 | |
| Prugen, INC. Pharmaceuticals | $61.00 | 2019-2020 | |
| Abbvie INC. | $52.97 | 2019 | |
| Genzyme Corporation | $39.28 | 2019 | |
| Galderma Laboratories, L.P. | $37.55 | 2019 | |
| Ucb, INC. | $33.37 | 2019 | |
| Allergan, INC. | $30.63 | 2019 | |
| Dermira, INC. | $23.11 | 2019 | |
| Dusa Pharmaceuticals, INC. | $23.07 | 2019 | |
| Janssen Scientific Affairs, LLC | $13.58 | 2019 | |
| Celgene Corporation | $12.75 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terri Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.